Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL)

PURPOSE: Overall survival (OS) is the definitive and best-established primary efficacy end point to evaluate diffuse large B-cell lymphoma (DLBCL) therapies, but it requires prolonged follow-up. An earlier end point assessed post-treatment would expedite clinical trial conduct and accelerate patient...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Clin Oncol
मुख्य लेखकों: Shi, Qian, Schmitz, Norbert, Ou, Fang-Shu, Dixon, Jesse G., Cunningham, David, Pfreundschuh, Michael, Seymour, John F., Jaeger, Ulrich, Habermann, Thomas M., Haioun, Corinne, Tilly, Hervé, Ghesquieres, Hervé, Merli, Francesco, Ziepert, Marita, Herbrecht, Raoul, Flament, Jocelyne, Fu, Tommy, Coiffier, Bertrand, Flowers, Christopher R.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Clinical Oncology 2018
विषय:
ORIGINAL REPORTS
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6532366/
https://ncbi.nlm.nih.gov/pubmed/29975624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.77.9124
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन